Amedisys (NASDAQ: AMED) reported Q3 EPS of $1.53, $0.16 better than the analyst estimate of $1.37. Revenue for the quarter came in at $553.5 versus the consensus estimate of $568.37 million.

GUIDANCE:

Amedisys sees FY2021 EPS of $5.88-$5.93, versus the consensus of $6.08. Amedisys sees FY2021 revenue of $2.2-2.205 billion, versus the consensus of $2.25 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.